PharmX Technologies Balance Sheet Health
Financial Health criteria checks 6/6
PharmX Technologies has a total shareholder equity of A$16.0M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$29.9M and A$13.9M respectively. PharmX Technologies's EBIT is A$244.0K making its interest coverage ratio 5.7. It has cash and short-term investments of A$13.1M.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | 5.7x |
| Cash | AU$13.14m |
| Equity | AU$15.97m |
| Total liabilities | AU$13.89m |
| Total assets | AU$29.86m |
Recent financial health updates
No updates
Recent updates
What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?
Feb 12
A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)
Jul 12At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?
May 11Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?
Nov 12At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?
Apr 29Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News
Mar 02Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Dec 13Financial Position Analysis
Short Term Liabilities: PHX's short term assets (A$16.4M) exceed its short term liabilities (A$12.0M).
Long Term Liabilities: PHX's short term assets (A$16.4M) exceed its long term liabilities (A$1.9M).
Debt to Equity History and Analysis
Debt Level: PHX is debt free.
Reducing Debt: PHX has not had any debt for past 5 years.
Debt Coverage: PHX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PHX has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 22:10 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmX Technologies Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caleb Weng | PAC Partners Securities Pty. Ltd. |